Anzeige
Mehr »
Montag, 16.06.2025 - Börsentäglich über 12.000 News
Von SOL zu BTC: Pioneer aktiviert automatisierte Bitcoin-Treasury über Kora AI Beta
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40EDR | ISIN: US46489V3024 | Ticker-Symbol: AAJ0
Tradegate
13.06.25 | 20:36
2,620 Euro
-4,38 % -0,120
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
PERSPECTIVE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PERSPECTIVE THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,6402,86015.06.
2,7002,80013.06.

Aktuelle News zur PERSPECTIVE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
PERSPECTIVE THERAPEUTICS Aktie jetzt für 0€ handeln
03.06.RBC Capital raises Perspective Therapeutics stock price target to $167
03.06.RBC Capital erhöht Kursziel für Perspective Therapeutics-Aktie auf 16 US-Dollar4
30.05.Perspective Therapeutics, Inc.: Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-a-NET at the 2025 ASCO Annual Meeting133Updated interim results with an additional ~16 weeks of follow-up on nine patients in Cohort 1 (2.5 mCi) and Cohort 2 (5.0 mCi) and initial safety findings in an additional 33 patients treated in...
► Artikel lesen
28.05.Perspective Therapeutics gibt Abstimmungsergebnisse bekannt22
28.05.Perspective Therapeutics, Inc. - 8-K, Current Report1
12.05.Perspective Therapeutics, Inc.: Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results376First of several clinical updates through mid-2026 accepted for presentation at the 2025 American Society of Clinical Oncology Annual Meeting, with recruitment progressing for all three of our clinical...
► Artikel lesen
12.05.Perspective Therapeutics, Inc. - 10-Q, Quarterly Report5
12.05.Perspective Therapeutics, Inc. - 8-K, Current Report2
11.05.Perspective Therapeutics Q1 2025 Earnings Preview3
29.04.Perspective Therapeutics, Inc. - 8-K, Current Report2
29.04.Perspective Therapeutics, Inc.: Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-a Positive Solid Tumors223SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for...
► Artikel lesen
23.04.Perspective Therapeutics, Inc.: Perspective Therapeutics Announces Acceptance of VMT-a-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting3
17.04.Perspective Therapeutics, Inc.: Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results1
11.04.Perspective Therapeutics, Inc. - 8-K, Current Report2
11.04.Perspective Therapeutics, Inc.: Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma162SEATTLE, April 11, 2025 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for...
► Artikel lesen
07.04.Truist cuts Perspective Therapeutics target to $10, maintains Buy7
28.03.Perspective Therapeutics, Inc. - 10-K/A, Annual Report4
27.03.Perspective Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans6
26.03.Perspective Therapeutics, Inc.: Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results290On track for multiple clinical updates through mid-2026, including further progress from two ongoing clinical programs and initiation of therapeutic dosing of potential new medicine, all based on...
► Artikel lesen
26.03.Perspective Therapeutics, Inc. - 8-K, Current Report2
Weiter >>
42 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1